Skip to main content

Table 3 P50 suppression amplitudes of S1, S2, and S1/S2 and latencies at different time points

From: Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot study

  TD (n = 31) TSC (n = 7)
Time point D0 D0 D91 D119
Trial Mean amplitude (SD) Mean amplitude (SD)
S1 amplitude 1.65 (1.01) 1.42 (.68) 1.98 (1.26) 1.67 (1.38)
S1 latency 61.35 (10.39) 62.67 (11.40) 63.33 (9.06) 62.67 (9.95)
S2 amplitude 1.00 (1.04) .88 (.70) 1.02 (.89) .74 (.52)
S2 latency 59.27 (15.45) 65 (9.97) 67.75 (14.44) 66.22 (14.12)
S1/S2 ratio .58 (.55) .73 (.50) .81 (.85) .65 (.52)
  1. Abbreviations: TD typically developing controls, TSC tuberous sclerosis complex